180 Life Sciences Corp
For the period ended Dec 27, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 27, 2024 · Filed Nov 12, 2024
Contents
Cover page
Show cover page
DEF 14A 1 ea0220686-def14a_180life.htm DEFINITIVE PROXY STATEMENT
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
**Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934
| Filed by the Registrant | ☒ |
|---|---|
| Filed by party other than the registrant | ☐ |
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
|---|---|
| ☐ | Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive additional materials |
| ☐ | Soliciting material under Rule 14a-12 |
**180 LIFE SCIENCES CORP.
**(Name of Registrant as Specified in Charter)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|
| ☐ | Fee paid previously with preliminary materials |
|---|
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
|---|
3000 El Camino Rd., Bldg. 4, Suite 200
Palo Alto, California 94306
November 12, 2024
To Our Stockholders:
The Board of Directors (“Board”) and officers of 180 Life Sciences Corp., a Delaware corporation (the “Company”), join us in extending to you a cordial invitation to attend the 2024 annual meeting of our stockholders, which we refer to as the annual meeting or the Meeting, to be held (subject to postponement(s) or adjournment(s) thereof):
| Date: | December 27, 2024 |
|---|---|
| Time: | 1:00 p.m. Pacific Time |
| Virtual Meeting Site: | https://agm.issuerdirect.com/ATNF |
You will not be able to attend the annual meeting physically. The annual meeting will be held via an audio teleconference. Stockholders may attend, vote and submit questions during the annual meeting via the Internet by logging in athttps://agm.issuerdirect.com/ATNF, with your Control ID and Request ID, and thereafter following the instructions to join the virtual meeting. In addition to voting by submitting your proxy prior to the annual meeting and/or voting online as discussed herein, you also will be able to vote your shares electronically during the annual meeting with your Request ID. Details regarding the business to be conducted are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement.
As permitted by the rules of the Securities and Exchange Commission (the “SEC” or the “Commission”), we have provided access to our proxy materials over the Internet. Accordingly, we are sending a Notice of Internet Availability of Proxy Materials, or E-proxy notice, on or about November 12, 2024, to our stockholders of record as of the close of business on November 12, 2024. The E-proxy notice contains instructions for your use of this process, including how to access our proxy statement and annual report and how to authorize your proxy to vote online. In addition, the E-proxy notice contains instructions on how you may receive a paper copy of the proxy statement and annual report or elect to receive your proxy statement and annual report over the Internet. We believe these rules allow us to provide you with the information you need while lowering the costs of delivery and reducing the environmental impact of the annual meeting.
The Notice of Annual Meeting and Proxy Statement, is also available athttps://www.iproxydirect.com/ATNF. This website also includes copies of our Annual Report on Form 10-K for the year ended December 31, 2023, which we refer to as the annual report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.
In connection with the annual meeting, you will be asked to consider and vote on certain proposals, which are more fully described in the accompanying proxy statement. Whether or not you plan to attend the annual meeting, we urge you to read the proxy statement (and any documents incorporated into the proxy statement by reference) and consider such information carefully before voting. The attached Notice of Annual Meeting and the Proxy Statement describe the business to be considered and acted upon by the stockholders at the annual meeting. Please review these materials and vote your shares.
Your vote is very important. Even if you plan to attend the annual meeting, if you are a holder of record of voting stock please submit your proxy by mail, fax, Internet or telephone as soon as possible to make sure that your shares are represented at the annual meeting. If you hold your shares of Company stock in “street name” through a bank, broker, or other nominee, you must vote in accordance with the voting instructions provided to you by such bank, broker, or other nominee, which include instructions for voting by Internet or telephone.
Our Board of Directors encourages your participation in 180 Life Sciences Corp.’s electoral process and, to that end, solicits your proxy with respect to the matters described in the Notice of Meeting and the proxy statement.
We look forward to seeing you on December 27, 2024. Your vote and participation in our governance is very important to us.
Sincerely,
/s/ Blair Jordan
Blair Jordan
Interim Chief Executive Officer and Director
Important Notice Regarding the Availability of Proxy Materials for the Virtual Annual Meeting of Stockholders to Be Held on December 27, 2024.
Our proxy statement and Annual Report on Form 10-K for the year ended December 31, 2023 are available at the following cookies-free website that can be accessed anonymously:https://agm.issuerdirect.com/ATNF. Stockholders may also vote prior to the meeting atwww.iproxydirect.com/ATNF.
**180 LIFE SCIENCES CORP.
**3000 El Camino Rd., Bldg. 4, Suite 200
Palo Alto, California 94306
**NOTICE OF 2024 ANNUAL MEETING OF STOCKHOLDERS
TO BE HELD ON DECEMBER 27, 2024
To the Stockholders of 180 Life Sciences Corp.:
We are pleased to provide you notice of, and to invite you to attend, the 2024 annual meeting of the stockholders of 180 Life Sciences Corp., a Delaware corporation (“180 Life”, the “Company”, “we” and “us”), which will be held on December 27, 2024, at 1:00 p.m., Pacific Time (subject to postponement(s) or adjournment(s) thereof), which we refer to as the annual meeting, or the “Meeting”. The meeting will be held virtually via live audio webcast athttps://agm.issuerdirect.com/ATNF. See also “Instructions For The Virtual Annual Meeting”, beginning on page 1. The annual meeting is being held for the following purposes:
| 1. | To elect three Class II directors to the Board of Directors (the “Board”) each to serve a term of two years and until their respective successors have been elected and qualified, or until such director’s resignation or removal. The Board has nominated for re-election the following incumbent Class II directors: Blair Jordan, Ryan Smith and Omar Jimenez. |
| 2. | To approve the adoption of the Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. The Board of Directors recommends that you approve and ratify the Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan. |
| 3. | To approve an advisory resolution on Named Executive Officer compensation. The Board of Directors recommends that you approve and ratify executive compensation. |
| 4. | To approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the conversion of Series B Convertible Preferred Stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b). The Board of Directors recommends that you approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the conversion of Series B Convertible Preferred Stock for purposes of complying with Nasdaq Listing Rules 5635(a) and (b). |
| 5. | To approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the exercise of outstanding warrants to purchase shares of common stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b). The Board of Directors recommends that you approve the issuance of more than 20% of the Company’s issued and outstanding common stock upon the exercise of outstanding warrants to purchase shares of common stock for the purpose of complying with Nasdaq Listing Rules 5635(a) and (b). |
| 6. | To ratify the appointment of M&K CPAs, PLLC, an independent registered public accounting firm, as the Company’s independent auditors for the fiscal year ending December 31, 2024. The Board of Directors recommends that you approve and ratify the appointment of M&K CPAs, PLLC as the Company’s independent auditors for the fiscal year ending December 31, 2024. |
| 7. | To transact such other business as may properly come before the annual meeting. |
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR ALL” FOR PROPOSAL ONE, AND “FOR” PROPOSALS TWO, THREE, FOUR, FIVE AND SIX.
Any action may be taken on any one of the foregoing proposals at the Meeting on the date specified above or on any date or dates to which the Meeting may be postponed or adjourned. We do not expect to transact any other business at the annual meeting. Our Board of Directors has fixed the close of business on October 31, 2024, as the record date for determining those stockholders entitled to vote at the annual meeting and any adjournment or postponement thereof. Accordingly, only common and preferred stock stockholders of record at the close of business on that date are entitled to notice of, and to vote at, the annual meeting.
We cordially invite you to attend the annual meeting. However, to ensure your representation at the annual meeting, please authorize the individuals named on your proxy card to vote your shares by calling the toll-free telephone number, faxing your proxy card or by using the Internet as described in the instructions included with your proxy card or voting instruction card. Alternatively, if you received a paper copy of the proxy card by mail, please complete, date, sign and promptly return the proxy card. This will not prevent you from voting at the meeting, but will help to secure a quorum and avoid added solicitation costs. If your shares are held in “street name” by your broker or other nominee, only that holder can vote your shares and the vote cannot be cast unless you provide instructions to your broker. You should follow the directions provided by your broker regarding how to instruct your broker to vote your shares. Your proxy may be revoked at any time before it is voted. Please review the proxy statement accompanying this notice for more complete information regarding the matters to be voted on at the meeting.
The enclosed proxy statement, notice of the availability of which is first being mailed to stockholders on or about November 12, 2024, is also available athttps://www.iproxydirect.com/ATNF. This website also includes our Annual Report on Form 10-K for the year ended December 31, 2023, which we refer to as the 2023 Annual Report. Stockholders may also request a copy of the proxy statement and our annual report by contacting our main office at (650) 507-0669.
Even if you plan to attend the annual meeting, we request that you submit a proxy by following the instructions on your proxy card as soon as possible and thus ensure that your shares will be represented at the annual meeting if you are unable to attend.
If you have any questions or require any assistance with voting your shares, please contact our proxy agent, Issuer Direct Corporation at (919) 481-4000, or 1-866-752-VOTE (8683).
By Order of the Board of Directors:
/s/ Blair Jordan
Blair Jordan
Interim Chief Executive Officer and Director
Palo Alto, California
November 12, 2024
IMPORTANT: WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, WE ASK YOU TO VOTE BY TELEPHONE, MAIL, FAX OR ON THE INTERNET USING THE INSTRUCTIONS ON THE PROXY CARD.
TABLE OF CONTENTS
| General Information | 1 |
|---|---|
| Information Contained in this Proxy Statement | 1 |
| Instructions For The Virtual Annual Meeting | 1 |
| Questions During the Annual Meeting | 1 |
| Technical Difficulties or Trouble Accessing the Virtual Meeting Website | 2 |
| Important Notice Regarding the Availability of Proxy Materials | 2 |
| Record Date and Shares Entitled to Vote | 2 |
| Voting Process | 3 |
| Providing and Revoking Proxies | 3 |
| Meeting Time and Location: Virtual Annual Meeting | 3 |
| Conduct at the Meeting | 4 |
| Voting Requirements for Each of the Proposals | 4 |
| Quorum | 5 |
| Board of Directors Voting Recommendations | 5 |
| Mailing Costs and Solicitation of Proxies | 6 |
| Inspector of Voting | 6 |
| Stockholders Entitled to Vote at the Meeting | 6 |
| Voting Instructions | 6 |
| Confidential Voting | 6 |
| Stockholder of Record and Shares Held in Brokerage Accounts | 6 |
| Multiple Stockholders Sharing the Same Address | 7 |
| Voting Results | 7 |
| Company Mailing Address | 7 |
| Other Matters | 7 |
| Background of the Company | 8 |
| Reverse Stock SplitS | 8 |
| Definitions | 8 |
| Forward-Looking Statements and Website Links | 9 |
| Incorporation by Reference | 9 |
| References to Additional Information | 9 |
| Voting Rights and Principal Stockholders | 9 |
| Security Ownership of Management and Certain Beneficial Owners and Management | 10 |
| Change of Control | 11 |
| Corporate Governance | 11 |
| Board Leadership Structure | 11 |
| Risk Oversight | 11 |
| Family Relationships | 12 |
| Arrangements between Officers and Directors | 12 |
| Other Directorships | 12 |
| Involvement in Certain Legal Proceedings | 13 |
| Board of Directors Meetings | 13 |
| Board Committee Membership | 13 |
| Audit Committee | 14 |
| Compensation Committee | 15 |
| Compensation Committee Interlocks and Insider Participation | 15 |
| Nominating and Governance Committee | 15 |
| Director Independence | 16 |
i
| Board Diversity Matrix | 17 |
|---|---|
| Website Availability of Documents | 17 |
| Stockholder Communications with the Board of Directors | 18 |
| Lead Independent Director | 18 |
| Executive Sessions of the Board of Directors | 18 |
| Code of Ethics | 18 |
| Policy on Equity Ownership | 18 |
| Insider Trading/Anti-Hedging Policies | 19 |
| Report of Audit Committee | 19 |
| Audit Committee Report | 20 |
| Information About Our Executive Officers and Directors | 21 |
| Executive Officers | 21 |
| Classified Board of Directors | 21 |
| Director Nominees | 22 |
| Director Qualifications | 24 |
| Director Whose Term Extends Beyond the 2024 Annual Meeting | 24 |
| Executive and Director Compensation | 25 |
| Summary Executive Compensation Table | 25 |
| Current Compensation Agreements | 27 |
| Jordan Consulting Agreement | 27 |
| Prior Employment Agreements | 28 |
| James N. Woody 180 Employment Agreement | 28 |
| James N. Woody Amended and Restated Employment Agreement (terminated); and Separation Agreement | 28 |
| Dr. Rothbard’s Employment Agreement (terminated); and Separation Agreement | 29 |
| Ozan Pamir Katexco Employment Agreement (Terminated) | 30 |
| Ozan Pamir Company Employment Agreement (Terminated) | 30 |
| Quan Anh Vu Executive Employment Agreement (terminated); and Separation Agreement | 31 |
| Description of Material Consulting Agreements | 32 |
| Service Agreement with Prof. Sir Marc Feldmann (former Co-Executive Chairman)(Terminated) | 32 |
| Consultancy Agreement and Consulting Agreement with Prof. Lawrence Steinman | 33 |
| Prof. Jagdeep Nanchahal Consulting Agreement | 34 |
| Salary Increases and Temporary Salary and Compensation Accruals | 36 |
| Payment of Back Pay; 2021 Bonuses and Increases in Salaries | 38 |
| 2024 Accruals | 38 |
| 2022, 2023 and 2024 Bonuses | 38 |
| Pay Versus Performance | 39 |
| Relationship Between “Compensation Actually Paid” and Performance | 41 |
| Compensation Actually Paid and Net Loss | 41 |
| Compensation Actually Paid and Cumulative TSR | 41 |
| Outstanding Equity Awards at Fiscal Year End | 42 |
| Potential Payments Upon Termination | 42 |
| Director Compensation | 42 |
| Board of Director Fees | 44 |
| Equity Compensation Plan Information | 45 |
| 2020 Omnibus Incentive Plan | 45 |
| 2022 Omnibus Incentive Plan | 45 |
| Certain Relationships and Related Party Transactions | 46 |
| Related Party Agreements | 46 |
| 360 Life Sciences Corp. Agreement - Related Party (Acquisition of ReFormation Pharmaceuticals Corp.) | 46 |
| Notice of Acceleration | 46 |
ii
| Service Agreement with Prof. Sir Marc Feldmann | 47 |
|---|---|
| Prof. Jagdeep Nanchahal Consulting Agreement | 47 |
| Prof. Lawrence Steinman Consultancy Agreement and Consulting Agreement | 47 |
| General and Administrative - Related Parties | 47 |
| Interest Expense on Loans Payable | 47 |
| Interest Income - Related Parties | 47 |
| Accrued Expenses - Related Parties | 47 |
| Research and Development Expenses – Related Parties | 48 |
| Accounts Payable – Related Parties | 48 |
| Registration Rights | 48 |
| Related Party Litigation | 49 |
| Indemnification Agreements | 52 |
| Related Party Transaction Policy | 52 |
| Delinquent Section 16(a) Reports | 53 |
| Summary of September 2024 Asset Purchase Agreement; Series B Convertible Preferred Stock and Warrants | 54 |
| Background | 54 |
| Series B Convertible Preferred Stock | 55 |
| Common Stock Purchase Warrants | 56 |
| Proposal 1 Election of Directors | 57 |
| General | 57 |
| General Director Qualifications | 57 |
| What Vote Is Required To Elect the Director Nominees | 57 |
| PROPOSAL 2 ADOPTION OF THE THIRD AMENDMENT TO THE 180 LIFE SCIENCES CORP. 2022 OMNIBUS INCENTIVE PLAN | 58 |
| General | 58 |
| Background and Purpose of the Amended Plan | 59 |
| Current Overview of Outstanding Equity Information | 59 |
| Summary of the Material Terms of the Amended Plan | 59 |
| Federal Income Tax Consequences | 64 |
| Unanimous Recommendation of the Board of Directors; Vote Required | 66 |
| Proposal 3 Approval of an Advisory Resolution on Named Executive Officer Compensation | 67 |
| General | 67 |
| Vote Required | 67 |
iii
| Proposal 4 for Purposes of Complying with Nasdaq Listing Rules 5635(a) and (B), to Approve the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Upon the Conversion of Series B Convertible Preferred Stock | 68 |
|---|---|
| Background | 68 |
| Reasons for Stockholder Approval | 68 |
| Consequences of Not Approving the Proposal | 69 |
| Description of the Common Stock that May be Issued | 69 |
| Resale Limitations | 69 |
| Vote Required | 69 |
| Proposal 5 for Purposes of Complying with Nasdaq Listing Rules 5635(a) and (B), to Approve the Issuance of More Than 20% of the Company’s Issued and Outstanding Common Stock Upon the Exercise of Warrants to Purchase Up to 3,000,000 Shares of Common Stock | 70 |
| Background | 70 |
| Reasons for Stockholder Approval | 70 |
| Consequences of Not Approving the Proposal | 70 |
| Description of the Common Stock that May be Issued | 70 |
| Resale Limitations | 70 |
| Vote Required | 70 |
| Proposal 6 Ratification of Appointment of Auditors | 71 |
| Change in Independent Registered Public Accounting Firm | 71 |
| General | 72 |
| Principal Accounting Fees and Services | 72 |
| Audit Committee Policy for Pre-approval of Independent Registered Public Accounting Firm Services | 73 |
| Pre-Approval Policies | 73 |
| Vote Required | 73 |
| OTHER MATTERS | 74 |
| Proxy Statement Proposals | 74 |
| Other Proposals and Nominations | 74 |
| Additional Filings | 75 |
| Other Matters to be Presented at the Annual Meeting | 75 |
| Interest of Certain Persons in or Opposition to Matters to Be Acted Upon: | 75 |
| Company Contact Information | 75 |
Appendixes:
**Appendix A —**Third Amendment to the 180 Life Sciences Corp. 2022 Omnibus Incentive Plan
Appendix B — Third Amended and Restated 180 Life Sciences Corp. 2022 Omnibus Incentive Plan
iv
**PROXY STATEMENT
FOR 2024 ANNUAL MEETING OF STOCKHOLDERS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.